Form 4: Onyia Jude reports multiple insider transactions in NBIX
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Onyia Jude reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 115,756 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 5,380 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
7,967 shares exercised/converted
Mixed
13 txns
Insider
Onyia Jude
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 2,690 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 2,717 | $0.00 | -- |
| Grant/Award | Stock Option | 55,119 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 9,669 | $0.00 | -- |
| Exercise | Common Stock | 2,690 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,452 | $124.12 | $180K |
| Exercise | Common Stock | 2,717 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,466 | $124.12 | $182K |
| Grant/Award | Common Stock | 19,935 | $0.00 | -- |
| Tax Withholding | Common Stock | 10,755 | $124.12 | $1.33M |
| Exercise | Restricted Stock Unit | 2,560 | $0.00 | -- |
| Exercise | Common Stock | 2,560 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,426 | $123.10 | $176K |
Holdings After Transaction:
Restricted Stock Unit — 5,380 shares (Direct);
Stock Option — 55,119 shares (Direct);
Common Stock — 19,801 shares (Direct)
Footnotes (1)
- Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
What insider transactions did NBIX Chief Scientific Officer Jude Onyia report?
Jude Onyia reported RSU vesting into common stock, tax-withholding share dispositions, and new equity awards. Activity included vested RSUs converting to shares, a performance-based share payout, a large stock option grant, and a new RSU grant with multi-year vesting schedules.
What new stock option did NBIX grant to Jude Onyia in February 2026?
Neurocrine granted Onyia a stock option covering 55,119 shares of common stock with a stated exercise price of $124.12. One forty-eighth of the option becomes vested and exercisable on March 13, 2026, with an additional one forty-eighth vesting and becoming exercisable each month thereafter.
How will Jude Onyia’s 9,669 new RSUs from NBIX vest?
The 9,669 restricted stock units will vest in four equal annual installments. One quarter of the units vests on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030, subject to the award’s terms and conditions remaining satisfied.